1. Home
  2. |Insights
  3. |FDA Provides Updated Instructions for Reporting Serious Adverse Events Under MoCRA

FDA Provides Updated Instructions for Reporting Serious Adverse Events Under MoCRA

Client Alert | 2 min read | 12.18.23

On December 14, 2023, the FDA issued an update with further instructions on  serious adverse event reporting under the Modernization of Cosmetics Regulation Act of 2022 (“MoCRA”), which is enforceable starting December 29, 2023.

Pursuant to MoCRA, a “responsible person” (i.e., “the manufacturer, packer, or distributor of a cosmetic product whose name appears on the label”) is required to submit a report on all serious adverse events associated with the intended use of a cosmetic product within 15 business days of receiving that information. Along with the report, responsible persons must submit a copy of the label and any medical or other information they received. And for the year following any reported event, responsible persons must submit any new medical information they receive within 15 business days of receipt. Under MoCRA, responsible persons also have the option of including a statement denying that the cosmetic product caused or contributed to the event; that statement will become part of the record in the event FDA releases adverse event information to the public.

A serious adverse event includes those that result in:

  • death,
  • threat to life,
  • inpatient hospitalization,
  • persistent or significant disability or incapacity,
  • congenital anomaly or birth defect,
  • infection, or
  • significant disfigurement.

Notably, serious adverse events do not include minor or transient reactions.

The FDA recommends that responsible persons submit these serious adverse event reports electronically by completing the updated MedWatch Form 3500A in accordance with the updated instructions. The FDA is currently developing a process for electronic submission of serious adverse event reports for cosmetic products, and it has promised to provide more information on the launch date for this electronic submission process “in the coming months.”

In the meantime, responsible persons can send the completed MedWatch Form 3500A, as well as all required information and any optional statement, by email at: CosmeticAERS@fda.hhs.gov or by mail to:

FDA CDER Mail Center
Attn: Cosmetics MedWatch reports
White Oak Campus, Building 22, G0207
10903 New Hampshire Ave.
Silver Spring, MD 20993

Contacts

Insights

Client Alert | 3 min read | 02.27.26

EEOC v. Coca-Cola Beverages Northeast, Inc.: Another Step Focused on the EEOC’s Goal of Eradicating Unlawful DEI-Related Practices

On February 17, 2026, the U.S. Equal Employment Opportunity Commission (EEOC) filed a complaint against Coca-Cola Beverages Northeast, Inc., in the United States District Court for the District of New Hampshire, alleging that the company violated Title VII of the Civil Rights Act of 1964 (Title VII) by conducting an event limited to female employees. The EEOC’s lawsuit is one of several recent actions from the EEOC in furtherance of its efforts to end what it refers to as “unlawful DEI-motivated race and sex discrimination.” See EEOC and Justice Department Warn Against Unlawful DEI-Related Discrimination | U.S. Equal Employment Opportunity Commission....

View All Insights